A Study to Assess the Safety and Pharmacokinetics of AD-104-A

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-104-A

Phase 1

Addpharma Inc.